Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

САЩ - английски - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

Австралия - английски - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - calcium carbonate,colecalciferol,risedronate sodium -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - calcium carbonate,colecalciferol,risedronate sodium -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: polysorbate 80; hyprolose; lactose monohydrate; calcium carbonate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; candelilla wax; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Малта - английски - Malta Medicines Authority

bayer limited 1st floor the grange offices the grange brewery road stillorgan co. dublin, a94 h2k7 , ireland - calcium carbonate, magnesium carbonate, heavy, alginic acid - chewable tablet - calcium carbonate 625 mg magnesium carbonate, heavy 73.5 mg alginic acid 150 mg - drugs for acid related disorders

Кения - английски - Pharmacy and Poisons Board

sanofi-aventis kenya p.o. box 20337-00200 nairobi - magnesium hydroxide + aluminium oxide - oral suspension in sachet - magnesium hydroxide 400mg + aluminium oxide 230mg… - aluminium antacids compounds

Ирландия - английски - HPRA (Health Products Regulatory Authority)

rorer pharmaceuticals limited - magnesium alginate aluminium hydroxide-magnesium carbonate gel magnesium carbonate potassium bicarbonate calcium carbonate - oral suspension - %v/v

Ирландия - английски - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - magnesium hydroxide; aluminium oxide, hydrated - chewable tablet - 400mg/400 milligram(s) - combinations and complexes of aluminium, calcium and magnesium compounds; ordinary salt combinations

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - magnesium hydroxide; aluminium hydroxide gel dried - oral suspension - 39mg/1ml ; 44mg/1ml